Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 309

1.

Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study.

Schuller E, Klade CS, Wölfl G, Kaltenböck A, Dewasthaly S, Tauber E.

Vaccine. 2009 Mar 26;27(15):2188-93. doi: 10.1016/j.vaccine.2008.12.062. Epub 2009 Feb 4.

PMID:
19200452
[PubMed - indexed for MEDLINE]
2.

Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study.

Kaltenböck A, Dubischar-Kastner K, Eder G, Jilg W, Klade C, Kollaritsch H, Paulke-Korinek M, von Sonnenburg F, Spruth M, Tauber E, Wiedermann U, Schuller E.

Vaccine. 2009 Jul 16;27(33):4483-9. doi: 10.1016/j.vaccine.2009.05.034. Epub 2009 May 30.

PMID:
19486955
[PubMed - indexed for MEDLINE]
3.

Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine.

Tauber E, Kollaritsch H, von Sonnenburg F, Lademann M, Jilma B, Firbas C, Jelinek T, Beckett C, Knobloch J, McBride WJ, Schuller E, Kaltenböck A, Sun W, Lyons A.

J Infect Dis. 2008 Aug 15;198(4):493-9. doi: 10.1086/590116. Erratum in: J Infect Dis. 2010 Apr 15;201(8):1278.

PMID:
18588481
[PubMed - indexed for MEDLINE]
Free Article
4.

Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age.

Kaltenböck A, Dubischar-Kastner K, Schuller E, Datla M, Klade CS, Kishore TS.

Vaccine. 2010 Jan 8;28(3):834-9. doi: 10.1016/j.vaccine.2009.10.024. Epub 2009 Oct 24.

PMID:
19857447
[PubMed - indexed for MEDLINE]
5.

Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.

Monath TP, Guirakhoo F, Nichols R, Yoksan S, Schrader R, Murphy C, Blum P, Woodward S, McCarthy K, Mathis D, Johnson C, Bedford P.

J Infect Dis. 2003 Oct 15;188(8):1213-30. Epub 2003 Oct 3.

PMID:
14551893
[PubMed - indexed for MEDLINE]
Free Article
6.

Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO, IC51.

Dubischar-Kastner K, Eder S, Buerger V, Gartner-Woelfl G, Kaltenboeck A, Schuller E, Tauber E, Klade C.

Vaccine. 2010 Jul 19;28(32):5197-202. doi: 10.1016/j.vaccine.2010.05.069. Epub 2010 Jun 10.

PMID:
20541581
[PubMed - indexed for MEDLINE]
7.

Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: multicenter randomized controlled trial.

Chokephaibulkit K, Sirivichayakul C, Thisyakorn U, Sabchareon A, Pancharoen C, Bouckenooghe A, Gailhardou S, Boaz M, Feroldi E.

Pediatr Infect Dis J. 2010 Dec;29(12):1111-7. doi: 10.1097/INF.0b013e3181f68e9c.

PMID:
20856164
[PubMed - indexed for MEDLINE]
8.

Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study.

Schuller E, Jilma B, Voicu V, Golor G, Kollaritsch H, Kaltenböck A, Klade C, Tauber E.

Vaccine. 2008 Aug 12;26(34):4382-6. doi: 10.1016/j.vaccine.2008.05.081. Epub 2008 Jun 17.

PMID:
18599165
[PubMed - indexed for MEDLINE]
9.

A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis.

Lyons A, Kanesa-thasan N, Kuschner RA, Eckels KH, Putnak R, Sun W, Burge R, Towle AC, Wilson P, Tauber E, Vaughn DW.

Vaccine. 2007 Apr 30;25(17):3445-53. Epub 2007 Jan 4.

PMID:
17241714
[PubMed - indexed for MEDLINE]
10.

Japanese encephalitis: update on vaccines and vaccine recommendations.

Wilder-Smith A, Halstead SB.

Curr Opin Infect Dis. 2010 Oct;23(5):426-31. doi: 10.1097/QCO.0b013e32833c1d01. Review.

PMID:
20581670
[PubMed - indexed for MEDLINE]
11.

T-cell activation and induction of antibodies and memory T cells by immunization with inactivated Japanese encephalitis vaccine.

Aihara H, Takasaki T, Toyosaki-Maeda T, Suzuki R, Okuno Y, Kurane I.

Viral Immunol. 2000;13(2):179-86.

PMID:
10892998
[PubMed - indexed for MEDLINE]
12.

The efficacy of mouse-brain inactivated Nakayama strain Japanese encephalitis vaccine--results from 30 years experience in Taiwan.

Yang SE, Pan MJ, Tseng HF, Liau MY.

Vaccine. 2006 Mar 24;24(14):2669-73. Epub 2005 Nov 10.

PMID:
16314007
[PubMed - indexed for MEDLINE]
13.

Long term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine IXIARO®, IC51.

Eder S, Dubischar-Kastner K, Firbas C, Jelinek T, Jilma B, Kaltenboeck A, Knappik M, Kollaritsch H, Kundi M, Paulke-Korinek M, Schuller E, Klade CS.

Vaccine. 2011 Mar 21;29(14):2607-12. doi: 10.1016/j.vaccine.2011.01.058. Epub 2011 Feb 1.

PMID:
21288804
[PubMed - indexed for MEDLINE]
14.

Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial.

Tauber E, Kollaritsch H, Korinek M, Rendi-Wagner P, Jilma B, Firbas C, Schranz S, Jong E, Klingler A, Dewasthaly S, Klade CS.

Lancet. 2007 Dec 1;370(9602):1847-53.

PMID:
18061060
[PubMed - indexed for MEDLINE]
15.

Immunizing children aged 9 to 15 months with live attenuated SA14-14-2 Japanese encephalitis vaccine in Thailand.

Chotpitayasunondh T, Sohn YM, Yoksan S, Min J, Ohrr H.

J Med Assoc Thai. 2011 Aug;94 Suppl 3:S195-203.

PMID:
22043776
[PubMed - indexed for MEDLINE]
16.

Superior immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (inactivated).

Kikukawa A, Gomi Y, Akechi M, Onishi T, Manabe S, Namazue J, Fuke I, Ishikawa T, Okuno Y, Ueda S.

Vaccine. 2012 Mar 16;30(13):2329-35. doi: 10.1016/j.vaccine.2012.01.054. Epub 2012 Jan 31.

PMID:
22306856
[PubMed - indexed for MEDLINE]
17.

Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.

Nasveld PE, Marjason J, Bennett S, Aaskov J, Elliott S, McCarthy K, Kanesa-Thasan N, Feroldi E, Reid M.

Hum Vaccin. 2010 Nov;6(11):906-14. doi: 10.4161/hv.6.11.12854. Epub 2010 Nov 1.

PMID:
20864814
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

[Study on the strategy of Japanese encephalitis immunization using live attenuated vaccine combined with inactivated vaccine].

Ma FB, Zheng L, Bi C, Tao H, Zhou YL, Zhang JL, Tang FY, Xie P, Zheng CZ, Peng WB, Jiang RJ.

Zhonghua Liu Xing Bing Xue Za Zhi. 2003 Feb;24(2):113-5. Chinese.

PMID:
12697111
[PubMed - indexed for MEDLINE]
19.

Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trials.

Torresi J, McCarthy K, Feroldi E, Méric C.

Vaccine. 2010 Nov 23;28(50):7993-8000. doi: 10.1016/j.vaccine.2010.09.035. Epub 2010 Oct 8.

PMID:
20934459
[PubMed - indexed for MEDLINE]
20.

Safety and immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (Inactivated) (JEBIK(®)V) in children.

Okada K, Iwasa T, Namazue J, Akechi M, Ueda S; JE Vaccine Clinical Study Group.

Vaccine. 2012 Sep 7;30(41):5967-72. doi: 10.1016/j.vaccine.2012.07.034. Epub 2012 Jul 25.

PMID:
22841478
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk